Sponsored Links
| Schering-Plough Highlights Boceprevir, Narlaprevir (SCH 900518) And PEGINTRON(R) Data At The American Association For The Study Of Liver Diseases |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Schering-Plough (NYSE: SGP) announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3. Read more: Pharma Industry / Biotech Industry News From Medical News Today
|